Luttrull J K, Musch D C, Spink C A
Eye (Lond). 2008 May;22(5):607-12. doi: 10.1038/sj.eye.6702725. Epub 2007 Feb 9.
To report the visual acuity and clinical outcomes of a pilot study of subthreshold diode micropulse (SDM) panretinal photocoagulation (PRP) for treatment of diabetic retinopathy.
A retrospective chart review of all patients undergoing PRP for diabetic retinopathy between April 2000 and February 2003 was performed. Treated conditions ranged from severe non-proliferative to severe proliferative diabetic retinopathy. An SDM PRP protocol designed to avoid detectable laser lesions was employed. Treatment failure end points included the development of vitreous haemorrhage or the performance of vitrectomy.
Ninety-nine eyes of 63 patients undergoing SDM PRP were identified. Median follow-up was 1.0 year (range of 0.3-2.7 years). Treatment sessions per eye ranged from 1 to 6 (with a median of two sessions per eye). Overall visual acuity remained unchanged. The probability of treatment failure end points at 12 months post-treatment was 12.5% for vitreous haemorrhage and 14.6% for vitrectomy (from Kaplan-Meier survival analysis). Age, sex, diabetes type, and baseline retinopathy status were not significantly associated with the risk of either failure event. No treatment complications were observed. No eye demonstrated any laser lesion detectable clinically or by fluorescein angiography postoperatively.
SDM pan retinal photocoagulation minimized retinal damage and treatment complications in the management of high-risk non proliferative and proliferative diabetic retinopathy. Visual loss was prevented with a low rate of vitreous haemorrhage and vitrectomy postoperatively. Further study of the safety, efficacy, and optimal treatment parameters of SDM pan retinal photocoagulation for diabetic retinopathy is warranted.
报告阈下二极管微脉冲(SDM)全视网膜光凝(PRP)治疗糖尿病性视网膜病变的初步研究的视力及临床结果。
对2000年4月至2003年2月间所有接受PRP治疗糖尿病性视网膜病变的患者进行回顾性病历审查。治疗的病情范围从严重非增殖性到严重增殖性糖尿病性视网膜病变。采用旨在避免可检测到的激光损伤的SDM PRP方案。治疗失败的终点包括玻璃体积血的发生或玻璃体切除术的实施。
确定了63例接受SDM PRP治疗的患者的99只眼。中位随访时间为1.0年(范围0.3 - 2.7年)。每只眼的治疗次数为1至6次(每只眼的中位数为2次)。总体视力保持不变。治疗后12个月时,玻璃体积血的治疗失败终点概率为12.5%,玻璃体切除术的为14.6%(来自Kaplan-Meier生存分析)。年龄、性别、糖尿病类型和基线视网膜病变状态与任何一种失败事件的风险均无显著相关性。未观察到治疗并发症。术后没有一只眼在临床上或通过荧光素血管造影显示有任何可检测到的激光损伤。
SDM全视网膜光凝在高危非增殖性和增殖性糖尿病性视网膜病变的管理中使视网膜损伤和治疗并发症最小化。术后玻璃体积血和玻璃体切除术发生率低,预防了视力丧失。有必要对SDM全视网膜光凝治疗糖尿病性视网膜病变的安全性、有效性和最佳治疗参数进行进一步研究。